Pharnext to Present Latest Scientific Data on its Two Lead Assets at Several International Scientific Conferences

Published: Jun 11, 2018

  • Drug candidate PXT3003, in a Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A, will be highlighted in six posters and two oral presentations
  • Drug candidate PXT864, in clinical development for the treatment of Alzheimer’s disease, will be highlighted in two posters and three oral presentations

Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.

Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.

The company will attend the following events:

European Academy of Neurology (EAN) congress
June 16-18, 2018 in Lisbon, Portugal

Two ePosters (oral communications)

Pharnext
Pharnext2

International Congress on Neuromuscular Diseases (ICNMD)
July 6-10, 2018 in Vienna, Austria

Two Posters

Pharnext0
Two Oral CommunicationsInnovations and State of the Art In Dementia Research meeting (ISADR)
July 16-18, 2081 in Valencia, Spain

Pharnext3

Pharnext4
One Oral CommunicationPeripheral Nerve Society (PNS) congress
July 22-25, 2018 in Baltimore, US

Four Posters

Pharnext5
If you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to contact@pharnext.comAlzheimer's Association International Conference (AAIC)
July 22-26, 2018 in Chicago, US

Two Posters

Pharnext6
View source version on businesswire.com: https://www.businesswire.com/news/home/20180611005795/en/
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit http://www.pharnext.com/

Contacts

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Media Relations (Europe)
Ulysse Communication
Bruno Arabian, +33 (0)1 81 70 96 30
barabian@ulysse-communication.com
or
Media Relations (U.S.)
RooneyPartners
Kate L. Barrette, +1 212 223 0561
kbarrette@rooneyco.com

Source: Pharnext SA

Back to news